{"organizations": [], "uuid": "e12e34f8f0c1c6aef99ad9b8183d5bef97be4c25", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-innate-pharma-announces-promising/brief-innate-pharma-announces-promising-anti-tumor-activity-of-monalizumab-with-cetuximab-in-scchn-idUSFWN1RU19F", "country": "US", "domain_rank": 408, "title": "BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-04-18T03:05:00.000+03:00", "replies_count": 0, "uuid": "e12e34f8f0c1c6aef99ad9b8183d5bef97be4c25"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-innate-pharma-announces-promising/brief-innate-pharma-announces-promising-anti-tumor-activity-of-monalizumab-with-cetuximab-in-scchn-idUSFWN1RU19F", "ord_in_thread": 0, "title": "BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN", "locations": [], "entities": {"persons": [], "locations": [{"name": "scchn", "sentiment": "none"}], "organizations": [{"name": "brief-innate pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - INNATE PHARMA SA:\n* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN\n* 8 PARTIAL RESPONSES IN 26 PATIENTS EVALUABLE FOR EFFICACY IN MONALIZUMAB PHASE I/II TRIAL\n* NUMBER OF RESPONSES NEEDED TO DECLARE TRIAL RESULT POSITIVE IS REACHED\n* COMBINATION WAS WELL TOLERATED, WITHOUT POTENTIATING CETUXIMAB-RELATED SIDE EFFECTS\n* TOTAL ENROLLMENT OF 40 PATIENTS NOW COMPLETED Source text: bit.ly/2J3tCYk Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "https://bit.ly/2J3tCYk"], "published": "2018-04-18T03:05:00.000+03:00", "crawled": "2018-04-18T18:19:55.031+03:00", "highlightTitle": ""}